HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.052928v1 49/11/1809    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iagaru, A. Articles by Goris, M. L. Search for Related Content PubMed PubMed Citation Articles by Iagaru, A. Articles by Goris, M. L.

⁹⁰Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from ¹¹¹In-Ibritumomab Pretreatment Imaging

¹ Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California; ² Departments of Radiology and Bioengineering, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, James H. Clark Center, Stanford, California; and ³ Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California

Correspondence: For correspondence or reprints contact: Andrei H. Iagaru, Stanford University Medical Center, 300 Pasteur Dr., Room H-0101, Stanford, CA 94305. E-mail: aiagaru{at}stanford.edu

Radioimmunotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL). ⁹⁰Y-ibritumomab is an antibody targeting CD20 receptors on the surface of lymphocytes. We present observations from our clinical experience with ⁹⁰Y-ibritumomab in the management of NHL. Methods: This was a retrospective study of 28 NHL patients treated with ⁹⁰Y-ibritumomab. There were 21 men and 7 women, 36–85 y old. A diagnostic dose of ¹¹¹In-ibritumomab was administered on day 0, and imaging followed immediately and at 24, 48, and 72 h. The doses of ⁹⁰Y-ibritumomab ranged from 629 to 1,258 MBq (17–34 mCi). Outcomes were compared with the findings of the ¹¹¹In-ibritumomab scans. Results: ⁹⁰Y-ibritumomab induced objective responses in 22 of 28 patients. A complete response was noted in 9 patients, a partial response in 9 patients, and a mixed response in 4 patients. Three patients had stable disease, and 3 patients had disease progression. ¹¹¹In-ibritumomab findings were positive in 19 patients and negative in 9 patients. A complete response was noted in 2 of 19 patients with positive findings and 7 of 9 with negative findings. A partial response was seen in 7 of 19 patients with positive findings and 1 of 9 with negative findings. Disease progression was observed in 3 of 19 patients with positive findings and 0 of 9 with negative findings. The remaining patients had a mixed response or no changes. Conclusion: A higher rate of complete response after ⁹⁰Y-ibritumomab treatment was seen in patients with negative ¹¹¹In-ibritumomab findings, whereas a higher rate of disease progression despite therapy was noted in patients with positive ¹¹¹In-ibritumomab findings. This observation suggests that patients with bulky disease may require more aggressive management.

Key Words: monoclonal antibodies • oncology • radioimmunoimaging • PET/CT • lymphoma • radioimmunotherapy

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				A. H. Iagaru, S. S. Gambhir, and M. L. Goris Reply: Tumor Metabolic Phenotypes on 18F FDG PET J. Nucl. Med., June 1, 2009; 50(6): 1011 - 1012. [Full Text] [PDF]

				C.-y. O. Wong and P.-l. Khong Tumor Metabolic Phenotypes on 18F FDG PET J. Nucl. Med., June 1, 2009; 50(6): 1010 - 1011. [Full Text] [PDF]

				D. M. Goldenberg Some like it hot: lymphoma radioimmunotherapy Blood, May 14, 2009; 113(20): 4823 - 4824. [Full Text] [PDF]

				R. M. Sharkey, O. W. Press, and D. M. Goldenberg A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy Blood, April 23, 2009; 113(17): 3891 - 3895. [Abstract] [Full Text] [PDF]